drugset / Trial / NCT01028560

Allergy Immunotherapy for the Reduction of Asthma

NCT01028560 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

In this clinical study we aim to determine the effect of allergy immunotherapy in decreasing asthma and allergy related disease in children who had multiple episodes of wheezing and who are at high risk for developing persisting asthma. These risks include a history of asthma in the parents, allergies to environmental allergens (such as dust mite, cockroach or mouse) and other allergic diseases such as eczema or food allergies. Allergy Immunotherapy is not new and has been practiced for many years to treat asthma and environmental allergies in older children and adults, but has not yet been systematically studied in young children.

Timeline

Start
2008-10
Primary completion
2015-04
Completion
2015-04

Outcome

Missed primary endpoint

registry No Immunotherapy, Receive Standard of Care Asthma Treatment vs Allergen Immunotherapy; p = 0.978 NCT01028560 ↗

paper There was no difference in asthma medication and symptom scores between the treatment or control groups over time. PMID 33418053 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allergen extracts Unknown — Subcutaneous

Indications